Your browser is no longer supported. Please, upgrade your browser.
Settings
REGN [NASD]
Regeneron Pharmaceuticals, Inc.
IndexS&P 500 P/E16.59 EPS (ttm)35.35 Insider Own1.40% Shs Outstand105.40M Perf Week0.53%
Market Cap62.52B Forward P/E14.62 EPS next Y40.10 Insider Trans-6.88% Shs Float101.58M Perf Month10.67%
Income4.00B PEG4.15 EPS next Q17.53 Inst Own90.10% Short Float1.39% Perf Quarter20.00%
Sales9.20B P/S6.80 EPS this Y65.30% Inst Trans3.20% Short Ratio1.85 Perf Half Y9.03%
Book/sh113.63 P/B5.16 EPS next Y-15.81% ROA24.50% Target Price632.91 Perf Year-6.97%
Cash/sh32.86 P/C17.84 EPS next 5Y4.00% ROE38.00% 52W Range441.00 - 660.00 Perf YTD21.37%
Dividend- P/FCF30.81 EPS past 5Y40.80% ROI23.90% 52W High-11.16% Beta0.14
Dividend %- Quick Ratio2.60 Sales past 5Y15.70% Gross Margin86.80% 52W Low32.96% ATR13.25
Employees9123 Current Ratio3.10 Sales Q/Q38.30% Oper. Margin43.40% RSI (14)65.35 Volatility2.02% 2.45%
OptionableYes Debt/Eq0.23 EPS Q/Q86.00% Profit Margin43.50% Rel Volume0.82 Prev Close586.88
ShortableYes LT Debt/Eq0.17 EarningsAug 05 BMO Payout0.00% Avg Volume761.97K Price586.35
Recom2.00 SMA202.23% SMA508.76% SMA20013.68% Volume624,106 Change-0.09%
Jun-29-21Initiated H.C. Wainwright Buy $703
Jan-25-21Upgrade BMO Capital Markets Market Perform → Outperform $630
Jan-13-21Upgrade The Benchmark Company Hold → Buy $590
Jan-08-21Upgrade Citigroup Neutral → Buy $635 → $575
Oct-05-20Upgrade Cantor Fitzgerald Neutral → Overweight $690
Aug-20-20Downgrade The Benchmark Company Buy → Hold
Jul-09-20Upgrade SunTrust Hold → Buy $400 → $750
May-26-20Upgrade Wells Fargo Equal Weight → Overweight $559 → $734
Apr-28-20Downgrade Citigroup Buy → Neutral $540 → $575
Apr-17-20Upgrade The Benchmark Company Hold → Buy $655
Apr-08-20Initiated The Benchmark Company Hold
Mar-31-20Initiated Wolfe Research Peer Perform
Feb-27-20Initiated Barclays Overweight $530
Feb-26-20Upgrade Canaccord Genuity Hold → Buy $550
Feb-26-20Downgrade Robert W. Baird Outperform → Neutral $410
Feb-25-20Upgrade Jefferies Hold → Buy $355 → $492
Feb-11-20Upgrade Argus Hold → Buy $430
Dec-24-19Initiated Raymond James Mkt Perform
Dec-16-19Downgrade Evercore ISI Outperform → In-line
Dec-13-19Upgrade Credit Suisse Neutral → Outperform $400
Jul-23-21 01:53PM  
Jul-22-21 02:36PM  
11:40AM  
10:37AM  
Jul-21-21 05:50PM  
01:43PM  
11:30AM  
09:31AM  
09:00AM  
07:23AM  
Jul-20-21 07:05PM  
02:51PM  
01:00AM  
Jul-19-21 02:01PM  
09:15AM  
Jul-16-21 01:37PM  
12:32PM  
12:03PM  
Jul-15-21 05:50PM  
02:58PM  
08:50AM  
Jul-14-21 01:49PM  
06:30AM  
Jul-12-21 03:09PM  
12:10PM  
Jul-11-21 06:43AM  
Jul-09-21 02:22PM  
Jul-08-21 01:57PM  
10:50AM  
Jul-07-21 11:38PM  
04:15PM  
01:46PM  
07:48AM  
Jul-06-21 02:21PM  
08:50AM  
07:11AM  
Jul-05-21 07:00AM  
06:30AM  
Jul-02-21 02:36PM  
01:39PM  
01:00PM  
12:00PM  
10:10AM  
09:00AM  
07:57AM  
Jul-01-21 02:05PM  
Jun-30-21 04:04PM  
03:30PM  
02:20PM  
12:14PM  
06:47AM  
06:42AM  
Jun-29-21 11:20AM  
09:55AM  
06:58AM  
Jun-28-21 04:12PM  
02:09PM  
11:40AM  
11:30AM  
11:09AM  
10:39AM  
10:02AM  
09:25AM  
06:09AM  
05:34AM  
03:19AM  
12:59AM  
Jun-26-21 11:16AM  
Jun-25-21 11:55AM  
08:51AM  
01:15AM  
01:00AM  
Jun-24-21 02:00PM  
Jun-23-21 01:48PM  
06:23AM  
Jun-22-21 04:15PM  
Jun-21-21 02:44PM  
Jun-18-21 02:04PM  
Jun-17-21 03:07PM  
10:27AM  
Jun-16-21 07:35PM  
03:26PM  
02:34PM  
01:48PM  
12:24PM  
11:51AM  
11:17AM  
08:23AM  
07:55AM  
07:05AM  
07:02AM  
01:08AM  
01:00AM  
01:00AM  
Jun-15-21 08:00PM  
03:20PM  
10:55AM  
Jun-14-21 01:47PM  
Jun-12-21 06:00AM  
Jun-11-21 11:40AM  
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis in adults, and asthma in adults and adolescents; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; and Kevzara solution for subcutaneous injection for treating rheumatoid arthritis in adults. In addition, the company offers Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer. Further, it offers Inmazeb injection for infection caused by Zaire ebolavirus; and develops product candidates for treating patients with eye, allergic and inflammatory, cancer, cardiovascular and metabolic, pain, infectious, and other diseases. The company has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services. It has collaborations with Zai Lab Limited; Intellia Therapeutics, Inc.; and Biomedical Advanced Research Development Authority. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
LAROSA JOSEPH JEVP General Counsel and SecretJul 06Sale580.003,3981,970,84013,182Jul 07 04:01 PM
LAROSA JOSEPH JEVP General Counsel and SecretJul 02Option Exercise179.1310,0001,791,30023,182Jul 07 04:01 PM
RYAN ARTHUR FDirectorJul 01Sale564.5010056,45023,491Jul 02 04:02 PM
BROWN MICHAEL SDirectorJun 25Option Exercise371.402,084773,9982,975Jun 28 04:01 PM
BROWN MICHAEL SDirectorJun 25Sale549.002,0841,144,116891Jun 28 04:01 PM
YANCOPOULOS GEORGEPresident and Chief ScientificJun 21Sale538.9080,00043,112,1412,108Jun 23 04:02 PM
BROWN MICHAEL SDirectorJun 14Option Exercise371.401,700631,3802,591Jun 16 04:02 PM
RYAN ARTHUR FDirectorJun 14Sale524.7610052,47623,591Jun 16 04:03 PM
BROWN MICHAEL SDirectorJun 14Sale525.001,700892,500891Jun 16 04:02 PM
McCourt MarionEVP CommercialJun 07Option Exercise342.931,000342,93018,038Jun 08 04:02 PM
GOLDSTEIN JOSEPH LDirectorJun 07Option Exercise374.121,930722,0527,821Jun 08 04:03 PM
McCourt MarionEVP CommercialJun 07Sale511.651,000511,65017,038Jun 08 04:02 PM
GOLDSTEIN JOSEPH LDirectorJun 07Sale525.001,9301,013,2505,891Jun 08 04:03 PM
STAHL NEILEVP Research and DevelopmentMay 17Sale519.4617,5219,101,46024,280May 18 04:04 PM
STAHL NEILEVP Research and DevelopmentMay 14Option Exercise148.8752,5007,815,57564,280May 18 04:04 PM
McCourt MarionEVP CommercialMay 07Option Exercise342.931,000342,93018,038May 10 04:02 PM
McCourt MarionEVP CommercialMay 07Sale495.631,000495,63017,038May 10 04:02 PM
VAGELOS P ROYDirectorFeb 23Option Exercise52.03250,00013,007,500487,088Feb 24 04:02 PM
RYAN ARTHUR FDirectorFeb 01Sale506.9210050,69223,691Feb 02 04:06 PM
BROWN MICHAEL SDirectorJan 25Option Exercise380.952,480944,7563,371Jan 27 04:06 PM
BROWN MICHAEL SDirectorJan 25Sale554.322,4801,374,714891Jan 27 04:06 PM
RYAN ARTHUR FDirectorJan 04Sale483.6010048,36023,543Jan 05 04:09 PM
YANCOPOULOS GEORGEPresident and Chief ScientificDec 30Option Exercise52.03398,07920,712,050908,303Dec 31 05:30 PM
RYAN ARTHUR FDirectorDec 01Sale520.4810052,04823,643Dec 02 04:09 PM
MURPHY ANDREW JEVP ResearchNov 17Sale542.736,6283,597,18847,136Nov 18 04:02 PM
MURPHY ANDREW JEVP ResearchNov 16Option Exercise30.6313,736420,73460,872Nov 18 04:02 PM
COLES N ANTHONYDirectorNov 13Option Exercise345.47113,800654Nov 13 05:57 PM
RYAN ARTHUR FDirectorNov 02Sale548.5410054,85423,743Nov 03 05:22 PM
MURPHY ANDREW JEVP ResearchOct 22Option Exercise38.565,185199,92647,136Oct 23 04:02 PM
McCourt MarionSVP CommercialOct 05Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
GOLDSTEIN JOSEPH LDirectorOct 05Option Exercise520.019,2124,790,33214,855Oct 06 04:09 PM
GOLDSTEIN JOSEPH LDirectorOct 05Sale600.009,2125,527,2005,643Oct 06 04:09 PM
McCourt MarionSVP CommercialOct 05Sale600.001,000600,00013,963Oct 06 04:07 PM
RYAN ARTHUR FDirectorOct 01Sale558.1310055,81328,343Oct 05 04:13 PM
BROWN MICHAEL SDirectorSep 22Option Exercise378.775,0901,927,9175,733Sep 23 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 22Sale552.362011,0475,643Sep 23 04:00 PM
BROWN MICHAEL SDirectorSep 22Sale552.361,000552,3609,349Sep 23 04:01 PM
BROWN MICHAEL SDirectorSep 22Sale552.365,0902,811,512643Sep 23 04:01 PM
GOLDSTEIN JOSEPH LDirectorSep 21Option Exercise376.7616,5746,244,37222,217Sep 23 04:00 PM
GOLDSTEIN JOSEPH LDirectorSep 21Sale549.8616,5549,102,4465,663Sep 23 04:00 PM
RYAN ARTHUR FDirectorSep 01Sale604.5810060,45828,443Sep 03 04:18 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 31Sale615.044,6722,873,46714,438Aug 31 04:37 PM
SING GEORGE LDirectorAug 31Sale612.0610,0006,120,55554,415Aug 31 04:36 PM
POON CHRISTINE ADirectorAug 28Option Exercise28.4440,0001,137,55041,433Aug 31 04:35 PM
POON CHRISTINE ADirectorAug 28Sale601.2240,00024,048,7151,433Aug 31 04:35 PM
LAROSA JOSEPH JEVP General Counsel and SecretAug 27Option Exercise52.0310,000520,30021,241Aug 31 04:37 PM
SING GEORGE LDirectorAug 25Option Exercise273.6712,7503,489,29297,165Aug 27 04:23 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 25Sale610.8927,10916,560,73820,001Aug 27 04:21 PM
SING GEORGE LDirectorAug 25Sale612.001,000612,0003,700Aug 27 04:23 PM
SING GEORGE LDirectorAug 25Sale607.2832,75019,888,51864,415Aug 27 04:23 PM
SING GEORGE LDirectorAug 24Option Exercise177.8210,0371,784,779104,452Aug 24 06:13 PM
SING GEORGE LDirectorAug 24Sale593.6320,03711,894,57784,415Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Option Exercise117.249,9631,168,071114,078Aug 24 06:13 PM
SING GEORGE LDirectorAug 21Sale605.1219,96312,080,04094,415Aug 24 06:13 PM
GOLDSTEIN JOSEPH LDirectorAug 21Sale617.181,000617,1805,643Aug 24 05:19 PM
McCourt MarionSVP CommercialAug 20Option Exercise342.931,000342,93014,963Oct 06 04:07 PM
SING GEORGE LDirectorAug 20Option Exercise57.1110,000571,100114,415Aug 24 06:13 PM
Van Plew Daniel PEVP & General Mgr Industrial OAug 20Option Exercise179.1375,00013,434,75095,001Aug 24 04:47 PM
SING GEORGE LDirectorAug 20Sale616.9121,00012,955,042104,415Aug 24 06:13 PM
McCourt MarionSVP CommercialAug 20Sale612.151,000612,15013,963Oct 06 04:07 PM
VAGELOS P ROYDirectorAug 11Sale602.9433,46020,174,35550,192Aug 13 04:02 PM
Landry Robert EEVP Finance CFOAug 04Sale654.46696455,50423,973Aug 05 05:07 PM
RYAN ARTHUR FDirectorAug 03Sale641.9310064,19328,543Aug 05 05:09 PM